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Abstract
Background: Adaptive servo-ventilation (ASV) therapy is a recent non-invasive positive pressure ventilation therapy
that was developed for patients with heart failure (HF) refractory to optimal medical therapy. However, it is likely
that ASV therapy at relatively higher pressure setting worsens some of the patients’ prognosis compared with optimal
medical therapy. Therefore, identification of optimal pressure settings of ASV therapy is warranted.
Case presentation: We present the case of a 42-year-old male with HF, which was caused by dilated cardiomyopathy,
who was admitted to our institution for evaluating his eligibility for heart transplantation. To identify the optimal
pressure setting [peak end-expiratory pressure (PEEP) ramp test], we performed an ASV support test, during
which the PEEP settings were set at levels ranging from 4 to 8 mmHg, and a heart rate variability (HRV)
analysis using the MemCalc power spectral density method. Clinical parameters varied dramatically during the
PEEP ramp test. Over incremental PEEP levels, pulmonary capillary wedge pressure, cardiac index and high-
frequency level (reflecting parasympathetic activity) decreased; however, the low-frequency level increased
along with increase in plasma noradrenaline concentrations.
Conclusions: An inappropriately high PEEP setting may stimulate sympathetic nerve activity accompanied by
decreased cardiac output. This was the first report on the PEEP ramp test during ASV therapy. Further research is
warranted to determine whether use of optimal pressure settings using HRV analyses may improve the long-term
prognosis of such patients.
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Background
As a non-invasive positive pressure ventilation therapy,
adaptive servo-ventilation (ASV) therapy was recently
developed for treating patients with heart failure that
was refractory to optimal medical therapy [1]. This ther-
apy could decrease preload and afterload, ameliorate im-
paired sympathetic nerve activity and increase cardiac
output, eventually facilitating left ventricular reverse re-
modeling and improving prognosis during short- or mid-
term study periods [2–8]. ASV therapy was originally
developed for treating sleep-disordered breathing (SDB)
but is currently being adopted for treating decompensated
heart failure, irrespective of the existence of SDB [9].
Recently, Cowie et al published a prospective random-
ized study and indicated that ASV therapy unexpectedly
decreased the survival rate compared with optimal med-
ical therapy for patients with heart failure and SDB [10].
In this study, they utilised ASV support at relatively
higher pressure settings to treat SDB. Therefore, the
clinical efficacy of routine ASV therapy in all patients
with heart failure has been controversial. Considering
that most of other ASV studies were conducted at the
default pressure setting, the optimal pressure settings
may be vital to attaining improved patient prognosis
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with ASV therapy. Here we present the case of a patient
with heart failure who was subjected to ASV support
testing; we attempted to utilise several pressure settings
and performed multiple haemodynamic tests, including
heart rate variability (HRV) analysis and measurement of
plasma catecholamine levels. To our knowledge, this is
the first report on investigation of optimal pressure set-
tings during ASV therapy.
Case presentation
A 42-year-old man with normal sinus rhythm was
admitted to our institution for the evaluation of his eligi-
bility for heart transplantation owing to advanced heart
failure , which was classified as New York Heart Associ-
ation functional class IV due to dilated cardiomyopathy
diagnosed by previous endomyocardial biopsy. He had
been receiving 10 mg/d of carvedilol, 2.5 mg/d of enala-
pril and 25 mg/d of spironolactone. At admission, he
had slight edema in bilateral leg, and his plasma B-type
natriuretic peptide level was 423 pg/mL. He had no his-
tory of hypertension or diabetes at admission. Transtho-
racic echocardiography showed that the left ventricular
diastolic dimeter was 67 mm, and as calculated by the
modified Simpson method, the left ventricular ejection
fraction was 23%; mild mitral and tricuspid regurgita-
tions were present as well. He had no SDB or active re-
spiratory infection. For further improvement of his heart
failure symptoms, he was subjected to ASV support test-
ing accompanied by haemodynamic assessment using
right-heart catheterization as well as HRV and noradren-
aline plasma level analyses at 10 days after the admission
(Fig. 1). An informed consent was obtained from the
patient beforehand.
An advanced bi-level positive airway pressure unit
(AutoSet-CS; ResMed, Sydney, Australia) together with a
best-fitting full-face mask (ResMed) was used for the
ASV support testing, as previously described [8]. Before
the final test, the patient received 5-min’s adaptation
period, during which ASV support at a default setting
was conducted for adaptation and confirmation of his
tolerability. During the ASV support testing, the peak
end-expiratory pressure (PEEP) was set at 4, 5, 6, 7 and
8 cmH2O, each one of which was within the minimum
range of 3–10 cmH2O (PEEP ramp test); each pressure
setting was maintained for 3 min.
During the PEEP ramp test, the pulmonary capillary
wedge pressure and cardiac index gradually decreased
with the increased PEEP settings, although a maximal
cardiac index was achieved at a PEEP of 5 cmH2O
(Fig. 1a and b). Other haemodynamic parameters, in-
cluding heart rate and systolic blood pressure, remained
unchanged from the baseline levels of 84 bpm and 110
mmHg, respectively, during the study period.
During the PEEP ramp test, we also performed an
HRV analysis (Fig. 1c and d). Power spectral analyses of
HRV were performed using the MemCalc power spectral
density method (MemCalc system; Suwa Trust Co,
Tokyo, Japan) [11–14]. Low frequency (LF) was defined
as a level of 0.04–0.15 Hz; high frequency (HF), which
reflected parasympathetic nerve activity, was defined
as a level of 0.15–0.40 Hz. The ratio of LF to HF
(LF/HF ratio) reflected sympathetic nerve activity. Al-
though the LF/HF ratio decreased upon the initiation
Fig. 1 Time course of haemodynamics and autonomic nerve activity during the PEEP ramp test. PEEP, peak end-expiratory pressure; ASV, adaptive
servo-ventilation; PCWP, pulmonary capillary wedge pressure; CI, cardiac index; LF, low-frequency; HF, high-frequency; NOR, noradrenalin
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of ASV support, the LF/HF ratio gradually increased
at increased PEEP levels (Fig. 1c) accompanied by in-
creased noradrenaline plasma levels (Fig. 1e). In contrast,
the HF level gradually decreased below the baseline at in-
creased PEEP levels (Fig. 1d). The patient complained of
mild discomfort at a PEEP of 8 cmH2O. No adverse events
occurred during the study period.
Discussion
Optimization of ASV therapy
The clinical efficacy of ASV therapy in all patients with
heart failure has been controversial. Although previous
studies have shown the efficacy of ASV therapy in
ameliorating symptomatic congestion, facilitating left
ventricular reverse remodeling and improving survival
rate of patients with mild-to-advanced heart failure
[3–8], recent studies have not been able to show any
definitive advantage of ASV therapy over optimal med-
ical therapy [2, 10]. Considering these results, optimal
patient selection and optimal pressure settings may be
key to successful ASV therapy.
Momomura et al performed a prospective randomized
study [2], which did not demonstrate the significant ad-
vantages of ASV therapy compared with optimal medical
therapy. Considering that the enrolled patients were
relatively less sick, the patients who were not receiving
optimal medical therapy may not be good candidates for
ASV therapy. Consistently, Yamada et al demonstrated
that cardiac output increased more in patients with
higher pulmonary capillary wedge pressures and mitral
regurgitation during ASV therapy [15]. Decreases in pre-
load and afterload during ASV therapy may more effect-
ively reduce intracardiac pressure in patients with
advanced heart failure than in those with mild heart fail-
ure . In contrast, we recently demonstrated that patients
with a severely remodeled left ventricle with long-term
heart failure rarely responded to ASV therapy [16]. Con-
sidering this evidence, further studies are warranted to
identify suitable patients for ASV therapy.
Changes in clinical variables during PEEP ramp test
Cowei et al administered ASV therapy, probably for
treating SDB, at relatively higher pressure settings (higher
than the default level), i.e., PEEP of 5 cmH2O, and found
that ASV therapy unexpectedly increased mortality [10].
Therefore, another concern was the optimization of pres-
sure settings during ASV therapy. Here, to our knowledge,
this is the first report on the PEEP ramp testing during
ASV support.
Positive pressure ventilation generally relieves elevated
intracardiac pressure due to the decrease in preload and
increase in cardiac output [2]. However, very high pres-
sure can reduce cardiac output, as shown in Fig. 1b.
Considering the haemodynamics of the patient, a PEEP
of 5–6 cmH2O would be the optimal pressure setting at
least in this case.
We recently showed the usefulness of real-time HRV
assessment during ASV support [17]. In the same
manner, we quantified the time course of autonomic
nerve activity during the PEEP ramp test. The LF/HF
ratio increased along with increase in PEEP (Fig. 1c).
Sympathetic nerve activity may be stimulated by de-
creased cardiac output due to the inappropriately re-
duced preload [13]. The HF level decreased gradually
along with increase in PEEP (Fig. 1d). Discomfort at
higher PEEP, similar to that at which the present pa-
tient complained, may reduce parasympathetic nerve
activity [17]. Based on the hypothesis that suppression
of sympathetic nerve activity and stimulation of para-
sympathetic nerve activity result in a favorable prog-
nostic effect in patients with heart failure [13, 18], a
PEEP of 5–6 cmH2O may also be the optimal pres-
sure setting at least in this case.
Future directions
The validity of this PEEP ramp test should be con-
firmed in many patients. Considering our previous
study results [13], we attempted each PEEP setting
for 3 min; however, the optimal period also should be
confirmed in a large-scale population study. We did
not measure the trend for the respiratory pattern in-
cluding the respiratory rate and variations in tidal
volume, which may affect sympathetic nerve activity
[6]. Such respiratory data also would strengthen the
importance of the PEEP ramp test. Also, we did not
measure blood gases at each pressure setting consid-
ering its invasiveness. Haemodynamics variables are
subject to the pH values and blood gases, and these
data may strengthen the interpretation of the PEEP
ramp test. Here, we sought the optimal pressure set-
tings for haemodynamics and autonomic nerve activ-
ity during short-term ASV support in a patient.
Although responses to long-term ASV therapy remain
unclear, the optimal pressure setting accompanied by
sufficiently preserved cardiac output and normalized
autonomic nerve activity may improve patient prog-
nosis. The optimal pressure setting may vary for each
patient, depending on age, co-morbidity, presence of
SDB and degree of heart failure . ASV therapy at the
optimal pressure setting for each patient, as deter-
mined by the PEEP ramp test, may improve patient
prognosis compared with ASV therapy performed at
the default pressure setting. A prospective randomised
trial of the PEEP ramp test is warranted.
Conclusions
We performed here for the first time a PEEP ramp test
during ASV therapy. Whether optimization of PEEP
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setting using HRV analyses may improve the long-term
prognosis should be confirmed in the prospective study.
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